1 |
Grambsch P and Therneau T (1994). Proportional hazards tests and diagnostics based on weighted residuals, Biometrika, 81 ,515-526.
DOI
|
2 |
Liang KY and Zeger SL (1986). Longitudinal data analysis using generalized linear models, Biometrika, 73, 13-22.
DOI
|
3 |
Surveillance, Epidemiology, and End results (SEER) program (www.seer.cancer.gov) SEER*Stat Database : Incidence - SEER 18 Regs custom data (with additional treatment fields), Nov 2018 Sub (1975-2016 varying) - Linked to county attributes - total US, 1969-2017 counties, national cancer institute, DCCPS, Surveillance research program, released April 2019, based on the November 2018 submission.
|
4 |
Irwin JO (1949). The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice, The Journal of Hygiene, 47, 188-189.
DOI
|
5 |
Tian L, Zhao L, and Wei LJ (2014). Predicting the Restricted mean event time with the subject's baseline covariates in survival analysis, Biostatistics, 15, 222-233.
DOI
|
6 |
Andersen PK, Hansen MG, and Klein JP (2004). Regression analysis of restricted mean survival time based on pseudo-observations, Lifetime Data Analysis, 10, 335-350.
DOI
|
7 |
Andersen PK and Perme MP (2010). Pseudo-observations in survival analysis, Statistical Methods in Medical Research, 19, 71-99.
DOI
|
8 |
Chen PY and Tsiatis AA (2001). Causal inference on the difference of the restricted mean lifetime between two groups, Biometrics, 57, 1030-1038.
DOI
|
9 |
Cox DR (1972). Regression models and life-tables (with discussion), Journal of Royal Statistical Society, Series A, 34, 187-220.
|
10 |
Guo C and Liang Y (2019). Analyzing restricted mean survival time using SAS/STAT, SAS Institute Inc., Cary, NC.
|
11 |
Royston P and Parmar MK (2011). The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt, Statistics in Medicine, 30, 2409-2421.
DOI
|
12 |
Zeger SL and Liang KY (1986). Longitudinal data analysis for discrete and continuous outcomes, Biometrics, 42, 121-130.
DOI
|
13 |
Zhao L, Tian L, Uno H, Solomon SD, Pfeffer MA, Schindler JS, and Wei LJ (2012). Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study, Clinical Trials, 9, 570-577.
DOI
|
14 |
Korea Central Cancer Registry (2019). National cancer center, Annual report of cancer statistics in Korea in 2017, Ministry of health and welfare.
|
15 |
National Cancer Information Center (2019). Cancer information service. from: https://www.cancer.go.kr/
|
16 |
Kaplan EL and Meier P (1958). Nonparametric estimation from incomplete observations, Journal of the American Statistical Association, 53, 457-481.
DOI
|
17 |
Nemes S, Bulow E, and Gustavsson A (2020). A brief overview of restricted mean survival time estimators and associated variances, MDPI Stats, 3, 107-119.
|
18 |
Prentice RL (1978). Linear rank tests with right censored data, Biometrike, 65, 167-180.
DOI
|
19 |
Ruhl J, Ward E, Hofferkamp J, et al (2019). Grade Manual. NAACCR, Springfield, IL 62704-4194.
|
20 |
Schoenfeld D (1982). Partial residuals for the proportional hazards regression model, Biometrika, 69, 239-241.
DOI
|